

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only, and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Biocytogen Pharmaceuticals (Beijing) Co., Ltd.



BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奥赛图(北京)医药科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

INSIDE INFORMATION COMPLETION OF THE ISSUE OF A SHARES; AND RESIGNATION OF EXECUTIVE DIRECTOR AND ELECTION OF EMPLOYEE DIRECTOR

I. COMPLETION OF THE ISSUE OF A SHARES

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

References are made to the announcements dated March 6, 2023, March 15, 2023, June 20, 2023, September 17, 2025, November 3, 2025, November 19, 2025, November 20, 2025 and November 27, 2025 and the circulars dated March 31, 2023 and November 3, 2025 of the Company, containing, among other things, related matters of the proposed initial public issue of A Shares (the “**Issue of A Shares**”) and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the above-mentioned announcements and circulars.

The Board is pleased to announce that, the Company has completed the Issue of A Shares. The A Shares of the Company will be listed and commence trading on the Sci-Tech Innovation Board of Shanghai Stock Exchange on December 10, 2025. Certain key information in respect of the Issue of A Share is as follows:

Place of listing and board of listing:	Sci-Tech Innovation Board of Shanghai Stock Exchange
Date of listing:	December 10, 2025
Stock abbreviation:	Biocytogen * (百奧賽圖)
Stock code:	688796
Total number of issued shares of the Company after the A Share Offering:	446,898,420 shares (comprising 336,116,500 A Shares and 110,781,920 H Shares)

In accordance with the requirements of the relevant authorities approving the Issue of A Shares, all Unlisted Shares of the Company issued before the Issue of A Shares have been registered with China Securities Depository and Clearing Corporation Limited as restricted circulating A Shares, which will rank *pari passu* with other issued A Shares of the Company, save for the lock-up period.

II. RESIGNATION OF EXECUTIVE DIRECTOR AND ELECTION OF EMPLOYEE DIRECTOR

The Board further announces that Dr. Zhang Haichao (“**Dr. Zhang**”) resigned as the executive director of the Company effective from December 10, 2025 due to internal work adjustments of the Company. Dr. Zhang has confirmed that she has no disagreement with the Board and there is no matter concerning her resignation from the aforesaid position that needs to be brought to the attention of the Shareholders.

The Board also announces that Ms. Li Yan (“**Ms. Li**”) was elected as an employee representative director (the “**Employee Director**”) of the 2nd session of the Board at the employee representative meeting of the Company in accordance with the Company Law, the Articles of Association and other relevant provisions as well as the results of the employee representative meeting held by the employee representatives of the Company on December 5 2025. The term of office of Ms. Li shall take effect from the date of listing of the Company’s A Shares on the Sci-Tech Innovation Board and expire on the date on which the term of office of the 2nd session of the Board expires.

The biographical details of Ms. Li are set out as follows:

Ms. Li Yan (李妍), aged 36, joined Group in December 2009 and has been a Supervisor of the Company since July 2019. She was appointed as chairman of the Supervisory Committee on December 15, 2020 and has been the director of the president’s office of the Company since July 2015. From March 2013 to July 2015, Ms. Li served as office director of our Company. From July 2012 to March 2013, Ms. Li was head of office of the Company.

Ms. Li has been a supervisor of Maple Veterinary Hospital (Beijing) Co., Ltd (楓葉寵物醫院(北京)有限公司) since March 2020 and of Eucure (Beijing) since September 2020. She has served as a supervisor of Biocytogen (Beijing) Biological Engineering Co., Ltd and Biocytogen Jiangsu Co., Ltd. since May 2023.

Ms. Li obtained a bachelor's degree in accounting from Renmin University of China (中國人民大學) in the PRC in January 2014.

As at the date of this announcement, saved as disclosed above, Ms. Li confirms that: (i) she has not held any directorships in any public companies, the securities of which are listed on any securities market in Hong Kong and/or overseas in the past three years, nor held any other major appointment and professional qualification; (ii) she does not hold any other position with the Company or its subsidiaries; (iii) she does not have any interests in the shares or securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iv) she does not have any relationship with other current directors, senior management or substantial or controlling Shareholders of the Company.

Currently, Ms. Li does not receive any remuneration from the Company in respect of her services rendered as a director. In the event that the Ms. Li begins to receive the remuneration with regard to the position of the Employee Director in future, her remuneration shall be determined with reference to the remuneration policy of the Company, her qualification and experience and other factors and will be disclosed in the financial reports of the Company in accordance with the requirement of the Listing Rules. Remuneration for Ms. Li in respect of her other positions of the Company shall be determined in accordance with the remuneration policy of the Company.

Saved as disclosed in this announcement, there is no other information relating to the appointment of Ms. Li as the Employee Director that need to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules, nor is there any matter that need to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Zhang for her valuable contributions to the Company during her term, and welcome Ms. Li on her appointment.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei

Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, December 9, 2025

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.

* *For identification purpose only*